SCHEMBL454023

SCHEMBL454023

O=C(O)CCCCP(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.58
NFKB1 P19838 3/20 0.55
PMP22 Q01453 2/20 0.55
TSHR P16473 1/20 0.55
TYMS P04818 1/20 0.55
SLC22A6 Q4U2R8 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
FOLH1 Q04609 3/20 0.48
LPAR3 Q9UBY5 3/20 0.48
LPAR2 Q9HBW0 1/20 0.48
CYP3A4 P08684 1/20 0.46
BLM P54132 1/20 0.46
GPR84 Q9NQS5 1/20 0.46
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
AKR1B1 P15121 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4534661 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4533111 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL2519566 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4527282 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4536540 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4535332 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL2939530 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4531743 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL20835969 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS
SCHEMBL4533190 0.97 TSHR (0.60) LMNANFKB1PMP22TSHRTYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119368142-A Zeolite molecular sieve for adsorbing and separating carbon dioxide and its preparing process 山东科技大学 2025-01-28 CN claimed
CN-111635528-B Three-dimensional network cross-linked phosphonated benzimidazole polymer proton exchange membrane and preparation method thereof 珠海冠宇电池股份有限公司 2023-04-07 CN claimed
CN-111349239-B Proton exchange membrane containing phosphonated hyperbranched polybenzimidazole and preparation method and application thereof 珠海冠宇电池股份有限公司 2023-01-06 CN claimed
CN-111574721-B Phosphonated polyolefin grafted benzimidazole polymer proton exchange membrane and preparation method and application thereof 珠海冠宇电池股份有限公司 2022-04-22 CN claimed
CN-111303437-B Phosphonated (polyolefin-g-hyperbranched polybenzimidazole) graft copolymer and preparation method and application thereof 珠海冠宇电池股份有限公司 2022-03-18 CN claimed
CN-111635528-A Three-dimensional network cross-linked phosphonated benzimidazole polymer proton exchange membrane and preparation method thereof 珠海冠宇电池股份有限公司 2020-09-08 CN claimed
CN-111574721-A Phosphonated polyolefin grafted benzimidazole polymer proton exchange membrane and preparation method and application thereof 珠海冠宇电池股份有限公司 2020-08-25 CN claimed
CN-111349239-A Proton exchange membrane containing phosphonated hyperbranched polybenzimidazole and preparation method and application thereof 珠海冠宇电池有限公司 2020-06-30 CN claimed
CN-111303437-A Phosphonated (polyolefin-g-hyperbranched polybenzimidazole) graft copolymer and preparation method and application thereof 珠海冠宇电池有限公司 2020-06-19 CN claimed
EP-2081600-A1 COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-07-29 EP claimed
WO-2008034815-A1 COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-03-27 WO claimed
EP-0971712-A1 COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION Smith & Nephew plc (GB) 2000-01-19 EP claimed
WO-1998035674-A1 COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION SMITH & NEPHEW PLC (GB) 1998-08-20 WO claimed
JP-1080849-A None JP disclosed
US-12590288-B2 Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response THE BROAD INSTITUTE, INC. (US) 2026-03-31 US disclosed
CN-119368142-B Zeolite molecular sieve for adsorbing and separating carbon dioxide and its preparing process 山东科技大学 2025-07-08 CN disclosed
WO-1995014681-A1 ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS PFIZER INC. (US) 1995-06-01 WO disclosed
EP-0494985-A1 A PROCESS FOR PREPARING PEROXYCARBOXYLIC ACIDS NOVO NORDISK A/S (DK) 1992-07-22 EP disclosed
WO-1991006574-A1 A PROCESS FOR PREPARING PEROXYCARBOXYLIC ACIDS NOVO NORDISK A/S (DK) 1991-05-16 WO disclosed
JP-S6480849-A ANALYSIS OF CHELATE AGENT SHIMADZU CORP 1989-03-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590288-B2 Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response GPR3, GALR3, NR4A3 LMNA 4387/4885NFKB1 1066/4885PMP22 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.